QuarterWatch™ relies on the adverse events reporting system (AERS), one of the strongest systems for monitoring drug adverse effects, for data. AERS can help identify adverse events and safety issues reported to medicines agencies (Health Canada, U.S. Food and Drug Administration, etc.) that were not observed in clinical trials. For example, in the U.S., AERS has been the source of information for most black-box warnings.
RSI has partnered with The Institute for Safe Medication Practices (ISMP) to publish QuarterWatch™, which monitors all adverse drug events reported to the FDA, identifies signals, and seeks to improve post-market surveillance.